US Stock Futures Signal Lower Start On Wall Street

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade. Data on import and export prices for September will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average dropped 79 points to 16,531.00, while the Standard & Poor's 500 index futures fell 8.70 points to 1,916.20. Futures for the Nasdaq 100 index dipped 35.75 points to 3,934.50.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index falling 1.07%, STOXX Europe 600 Index dropping 1.57%. German DAX 30 index slipped 2.02%, French CAC 40 Index fell 1.46% and London's FTSE 100 Index dropped 1.28%. Italy's industrial production increased 0.3% on the month in August. French industrial production came in unchanged in August versus July. In Asian markets, Japan's Nikkei Stock Average dropped 1.15%, Hong Kong's Hang Seng Index tumbled 1.90%, China's Shanghai Composite Index fell 0.62% and India's BSE Sensex dipped 1.28%.
Broker Recommendation
Analysts at Mizuho Securities downgraded Auxilium Pharmaceuticals
AUXL
from Buy to Neutral and lowered the price target from $37.00 to $33.00. Auxilium Pharma shares jumped 9.01% to close at $32.44 yesterday.
Breaking news
  • Indian company Infosys INFY reported better-than-expected second-quarter profit. To read the full news, click here.
  • Novartis NVS today announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1]. To read the full news, click here.
  • Chiquita Brands International CQB today announced in accordance with Rule 8.1 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, that as of October 8, 2014, its President and Chief Executive Officer, Edward F. Lonergan acquired 63,511 shares.To read the full news, click here.
  • Isis Pharmaceuticals ISIS today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsMizuho SecuritiesUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...